We Demand More:
The treatments currently available for cancer are just not good enough.
Most treatments on the market make cancer patients sick before they can get better.
We have an innovative solution that has been overlooked. Together with our investors and partners, our “Interceptor” approach will revolutionize the direction of cancer treatment, with safety in mind.
Immunotherapies have transformed cancer R&D. Pharmaceutical companies are actively seeking early-stage drugs with unique MOA for stand-alone or combination therapies. Oncology immunotherapy sales are steadily growing and predicted to generate $111B per year by 2020. Our treatment provides an opportunity in the immunotherapy space for investors and/or partners.